Fluorouracil-platinum(IV) prodrugs demonstrate enhanced cytotoxicity and multimechanistic anticancer effects against cisplatin-resistant colorectal cancer cells in vitro.
Do fluorouracil-platinum(IV) prodrugs improve cytotoxicity against cisplatin-resistant colorectal cancer cells compared to cisplatin and 5FU?
Fluorouracil-platinum(IV) prodrugs show potential as multimechanistic chemotherapeutics for cisplatin-resistant colorectal cancer.
Tasa de eventos absoluta: 0% vs 0%
Fluorouracil-platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs PtIVP-5FUMeOBut and PtIV56-5FUMeOBut were actualized by derivatising the clinical drug 5-fluorouracil (5FU) and coordinating it to platinum(IV) complexes, leveraging the established cytotoxicity of their platinum(II) precursors, PtIIPHENSS and PtII56MESS. The rationale behind this design is to combine the DNA synthesis-disrupting antimetabolite activity of 5FU with platinum-based cytotoxicity, aiming to enhance therapeutic efficacy. This study evaluates the in vitro potency of PtIVP-5FUMeOBut and PtIV56-5FUMeOBut in colorectal cancer models, assessing their cellular uptake, cytotoxicity, and effects in 3D spheroid cultures. Comparative analyses with cisplatin and 5FU explore their impact on cell survival, reactive oxygen species production, mitochondrial membrane potential, and cell-cycle progression. Mechanistic insights are further examined through apoptosis and necrosis assays, proteomic profiling, and western blot analysis of key signalling pathways. These findings contribute to the preclinical development of fluorouracil-platinum(IV) prodrugs as potential candidates for cancer therapy.
Elias et al. (Fri,) reported a other. Fluorouracil-platinum(IV) prodrugs demonstrate enhanced cytotoxicity and multimechanistic anticancer effects against cisplatin-resistant colorectal cancer cells in vitro.